|
|
|
Cadila Healthcare Limited |
|
Cadila is a well known research-oriented, technology-driven pharmaceutical company focused on the research areas of biotechnology, formulations and Active Pharmaceutical Ingredients (APIs), etc. It has marketing offices in more than 4 countries and has significant presence in over 45
countries.
It is into the operations of softgel, telecommunications, hospital disposables, instrumentations and diagnostics, etc. Cadila is among the leading pharma companies with over 400 multi-dimensional formulations of major therapeutics groups in human and over 15 in animal health. Cadila has a strong formulation development base and is the first manufacturer of Immuvac, a unique immunomodulator.
|
|
In Asia, it is the unrivaled manufacturer of 'SULFOLANE' (Tetramethylene Sulfone). Its Bulk Actives (APIs) manufacturing facility is approved under ISO 9002 and it offers facilities for contract research. It has achieved leadership in Indian Generic market as well as in Distribution management.
The R&D facility of Cadila is spread in an area of 45,000 Sq.ft. and has human resources of 150
scientists. It has collaboration with more than 30 leading R&D centers in the country. It has introduced RABEPRAZOLE and FOSINOPRIL formulations in India. Its strong marketing & sales team consists of 2, 37318 pharmacies 1900 wholesalers, 25 C&S agents, and 1,300 field employees
Cadila has the following brands:
- Envas
- Aciloc
- Lmx, Symbiotik, Clax
- Rabeloc, RD, Zaso, Mixulin, Montelast and Nodon
Corporate & Registered Office
CADILA CORPORATE CAMPUS
Sarkhej-Dholka Road,
Bhat, Ahmedabad-382 210, INDIA.
Phone: +91-2718-225001 (15 Lines)
Fax: +91-2718-225039
e-mail: website@cadilapharma.co.in
Quarterly Results of Cadila
Quarterly Results (Rs. in Millions) |
|
Dec 2006 (3 rd quarter) |
Sept 2006
(2nd quarter) |
Dec 2005
(3 rd quarter) |
|
Sales Turnover |
3749 |
4037 |
3328 |
Other Income |
281 |
194 |
179 |
Total Income |
4030 |
4231 |
3507 |
Total Expenditure |
3199 |
3287 |
2773 |
Operating Profit |
831 |
944 |
734 |
Interest |
44 |
32 |
91 |
Gross Profit |
787 |
912 |
643 |
Depreciation |
172 |
167 |
153 |
Tax |
90 |
90 |
48 |
Reported PAT |
525 |
655 |
429 |
*Source: economictimes.indiatimes.com
Quarterly Results (in %) |
|
% Change (Over Sep 2006)
|
% Change (Over Dec 2005)
|
Sales Turnover |
-7.13 |
12.65 |
Other Income |
44.85 |
56.98 |
Total Income |
-4.75 |
14.91 |
Total Expenditure |
-2.68 |
15.36 |
Operating Profit |
-11.97 |
13.22 |
Interest |
37.5 |
-51.65 |
Gross Profit |
-13.71 |
22.4 |
Depreciation |
2.99 |
12.42 |
Tax |
|
|
Reported PAT |
-19.85 |
22.38 |
*Source: economictimes.indiatimes.com
Annual Results of Cadila:
Annual Unaudited Results (Rs. in Millions) |
|
(12 Months) |
(12 Months) |
% Changes |
Sales Turnover |
11,253.00 |
11,160.00 |
0.83 |
Other Income |
785 |
925 |
-15.14 |
Total Income |
12,038.00 |
12,085.00 |
-0.39 |
Total Expenditure |
9,643.00 |
9,598.00 |
0.47 |
Operating Profit |
2,395.00 |
2,487.00 |
-3.7 |
Interest |
202 |
232 |
-12.93 |
Gross Profit |
2,193.00 |
2,255.00 |
-2.75 |
Depreciation |
565 |
531 |
6.4 |
Tax |
190 |
222 |
-14.41 |
Reported PAT |
1,314.00 |
1,411.00 |
-6.87 |
*Source: economictimes.indiatimes.com
|
|
|
|
|
|
|
|
|
|
